J. Sands, A.E. Lisberg, X. Le, E. Shum, L. Hendriks, H.A. Yu, J.W. Riess, Y. Goto, Z. Piotrowska, K.H. Tang, J. Harper, S. Pölsterl, H.J. Failmezger, D. Vonficht, Rachel Chiaverelli, J.M. Lehman, P.G. Fraenkel, H. Zebger-Gong, S.B. Goldberg, M-J. Ahn
Dato-DXd received accelerated US FDA approval for treatment of EGFRm NSCLC based on a pooled analysis of EGFRm cohorts from TROPION-Lung05 (TL05; NCT04484142) and TROPION-Lung01 (TL01; NCT04656652). TROP2 NMR status by QCS was associated with clinical outcomes with Dato-DXd in patients (pts) with non-squamous, non-actionable genomic alteration (NSQ non-AGA) NSCLC who were treated in TL01 and TROPION-PanTumor01 (NCT03401385). Here we report data assessing TROP2 NMR status in pts with EGFRm NSQ NSCLC receiving Dato-DXd in TL01 and TL05 or osi + Dato-DXd in the ORCHARD study (NCT03944772).